A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma

BACKGROUND: There is clinical evidence to suggest that tumour necrosis factor-α (TNF-α) may be a therapeutic target in renal cell carcinoma (RCC). Multi-targeted kinase inhibitors, such as sorafenib and sunitinib, have become standard of care in advanced RCC. The anti-TNF-α monoclonal antibody infli...

Descripción completa

Detalles Bibliográficos
Autores principales: Larkin, J M G, Ferguson, T R, Pickering, L M, Edmonds, K, James, M G, Thomas, K, Banerji, U, Berns, B, de Boer, C, Gore, M E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967062/
https://www.ncbi.nlm.nih.gov/pubmed/20842130
http://dx.doi.org/10.1038/sj.bjc.6605889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967062/
https://www.ncbi.nlm.nih.gov/pubmed/20842130
http://dx.doi.org/10.1038/sj.bjc.6605889

Ejemplares similares